| INTRODUCTION
Mitochondria, the powerhouse of the cells, play a pivotal role in the final oxidation of metabolites such as fatty acids (FA) and glucose.
The mitochondrial oxidative phosphorylation (OXPHOS) is responsible for the production of most cellular total energy. In addition, it is also involved in the regulation of intrinsic signalling pathways of apoptosis. Since it is involved in the generation of energy in the form of adenosine triphosphate (ATP), the mitochondrial dysfunction can result in the depletion of ATP level that may eventually lead to the loss of cell membrane integrity. Consequently, this may allow entry of toxic substances into the cells, causing a progressive necrosis.
The mitochondrial inefficiency was first described in Leiber's optic neuropathy in 1871. 1 Later in 1962, Luft et al 2 reported a mitochondrial disease in a euthyroid patient suffering from hypermetabolism and myopathy. Thereafter, this energy producing cellular organelle was reported to take part in the pathogenesis of numerous human diseases. The primary aetiology can be attributed to the leakage of electrons from electron transport chain (ETC) complex to oxygen molecule resulting in the formation of free radicals and reactive oxygen species (ROS). The role of ROS, principally hydrogen peroxide (H 2 O 2 )
at the physiological level, has been demonstrated to affect cellular differentiation, activation of immunity, and metabolic adaptation during hypoxia. 3 During hypoxia, mitochondrial ROS stabilizes the hypoxiainducible factor in the cytosol and, thus, triggers the cellular adaptation. 4, 5 However, the excessive production of ROS under various pathological conditions can damage the mitochondrial proteins, lipids, and DNA. 6 Liver failure is a fatal condition with unidentified aetiology. Nonalcoholic fatty liver disease (NAFLD) is a condition where there is no or little alcohol consumption (<20 g/d in females and <40 g/d in males).
It is one of the most common chronic liver diseases affecting one-third of adults in Western countries and comprises a broad spectrum of diseases ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) and fibrosis. Obesity, diabetes, and metabolic syndrome are other medical conditions that are frequently associated with NAFLD. This review discusses the recent updates on the role of mitochondria in NAFLD and the potential of mitochondria-targeted therapy.
| MITOCHONDRIA IN NAFLD
Non-alcoholic fatty liver disease has been proposed as a pathogenetic process that could affect multiple organs. The first effect is the accumulation of hepatic fat, which eventually leads to insulin resistance (IR), followed by the secondary effects comprising mitochondrial dysfunction, oxidative stress, and adipocytokine imbalance. Therefore, NAFLD is a hepatic manifestation of the metabolic syndrome. Wei and colleagues considered NAFLD as a 'mitochondrial disorder'. 9 Many patients suffering from NASH have been reported to carry abnormal morphological changes in the hepatic mitochondria such as crystalline inclusions of unknown composition. 10 Buzzetti et al 11 recently suggested a "multiple hit" hypothesis for the pathogenesis of brane. An excess of saturated FA in the phospholipid of mitochondrial membrane adversely influences the sensitivity of carnitine acyltransferase I to its inhibitor malonyl~CoA leading to an unbalanced transport of long-chain FA into the matrix and, thereby, the beta-oxidation. In addition to triggering the membrane lipid peroxidation, the excessive ROS can cause the release of pro-inflammatory molecules, such as a tumour necrosis factor-alpha (TNF-α), from the Kupffer cells. 25 The released TNF-α can activate the specific redox-sensitive kinases to further upregulate the pro-inflammatory pathways that ultimately result in IR. 26 Sookoian et al 27, 28 while studying the epigenetic Apoptosis in the liver cells can be carried out by several intrinsic and extrinsic pathways. [31] [32] [33] [34] [35] An increased expression of apoptotic proteins and enzymes, such as Bcl-2, was recorded in the murine models of fatty liver disease. 32, 36 The Bcl-2 proteins, like Bax, are porins, which perforate the outer mitochondrial membrane and facilitate apoptosis through the efflux of cytochrome c. 32 The intrinsic pathways are triggered by DNA damage, depletion of growth factors, stimulation of oncogenes and most importantly by the release of cytochrome c, which altogether disintegrates the mitochondrial membrane and activates caspases. 31, 33 The saturated FAs can also induce apoptosis in hepatocytes by directly activating Jun N-terminal kinase (JNK) and mitochondrial pathways.
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Oxidative stress can induce liver damage and the activation hepatic stellate cells (HSC) and Kupffer cells leading to liver fibrosis.
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Generation of ROS in the mitochondria and the induction of hepatocyte inflammation are depicted in Figure 2 . In NAFLD, chronic oxidative stress causes damage to the fat-laden hepatocytes. The widespread protein and lipid peroxidation reduces the hepatic antioxidant capacity, shifts the intracellular redox status toward an oxidized state. Further, the activation of the peroxisome proliferator-activated receptor-α transcription factor induces the expression of mitochondrial uncoupling protein 2 (UCP2), resulting in the depletion of cellular ATP reserves. TNF-α, ROS, and the products of lipid peroxidation are involved in several vicious cycles resulting in the blocking of electron flow in the respiratory chain that further depletes the ATP and triggers the lesions in NASH. 41 The expression of UCP2 is also increased by excessive hepatic TNF-α. ), hydroxyl (OH . ) radicals are generated from defect in the oxidative phosphorylation. The influx of calcium (Ca ++ ) induces the nitric oxide (NO . ) production which along with the O 2 _. produces peroxynitrite (ONOO¯). The ROS are diffused out from the mitochondria and activate the nuclear factor-kappa B (NF-kB). ROS damage the DNA which is further digested by DNase. Toll like receptor-9 (TLR-9) will be activated by the damaged DNA. Furthermore, the accumulated ceramide and Diacyl glycerol (DAG) during steatosis induce the NF-kB to produce cytokines and, thereby, inflammation superoxide radical is one of the important mediators of free radical toxicity. 43 predisposes the liver to NASH. The high-fat diet was found to be correlated with lowering of the Sirt1 level in a rat NAFLD model. 58 The levels of mitochondrial transcription factor A, one of the main transcription factors for mtDNA synthesis and its stability, have been recorded to be low in the fatty liver. 59 Some previous preclinical studies have demonstrated the declined activities of complexes I to IV of ETC in liver toxicities. 13 Lane et al 
| MITOCHONDRIA-TARGETED AGENTS
Randomized vs placebo-controlled double-blinded trials have been conducted to assess the efficacy of several drugs in NAFLD patients.
Pioglitazone and metformin are very beneficial and hence have been recommended for the treatment in selected patients. 70 However, the activity in NAFLD non-diabetic patient without and with NASH, respectively. 71 Similarly, peroxisome proliferator-activated receptor gamma agonist, pioglitazone (30 mg, once daily for 48 weeks) was efficient in alleviating the NASH in NAFLD patients without diabetes. 72 A similar dose of pioglitazone combined with calorie restriction (500 kcal/d) for 24 weeks in the subjects with type 2 diabetes or impaired glucose tolerance led to better outcomes. 73 The metformin poorly improved the inflammation but pioglitazone was comparatively more efficient in improving the ballooning degeneration.
Besides the beneficial effects, the adverse side effects of pioglitazone, such as weight gain, fluid retention, and osteopenia, were also observed. 74 Therefore, it is generally recommended to modify the lifestyle through regular exercise and emphasis on gradual weight loss through diet. 75 Antioxidant therapy is one of the approaches employed to ameliorate the oxidative stress-induced liver toxicity. Among these, vitamin E has been the most widely explored antioxidant to treat patients with NAFLD and NASH. 76 It can significantly improve the liver function and histological changes in NAFLD/NASH patients. 77 Sanyal et al 78 reported that vitamin E was effective in the non-diabetic adult with NASH. However, there are contradictory reports on its effectiveness. 79 Sarkhy et al 80 could not find any beneficial effect of vitamin E in normalizing serum ALT in a meta-analysis. Further, the children with NAFLD did not improve by vitamin E therapy. 81 Therefore, its multiple responses, long-term tolerance, and efficacy in NAFLD patients with diabetes or NASH-related cirrhosis have not been elucidated yet.
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Previous experimental studies demonstrated several plant derived antioxidants such as resveratrol, coumestrol, anthocyanidins, epigallocatechin gallate, curcumin, allyl-isothiocyanate, and carotenoid were effective in the NAFLD therapy. Most of them were able to control the de novo lipogenesis and increase the proteins in lipolytic pathway.
Furthermore, they were effective to maintain mitochondrial functions (Table 1) .
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Antioxidants Effect on mitochondria
Resveratrol
Increases complex I activity results in the increase of mitochondrial NAD + /NADH ratio and enhances the SIRT3-dependent stimulation of Krebs cycle and β-oxidation. 100 
Coumestrol
Increases biogenesis such as mitochondrial number and function by activating SIRT1.
Anthocyanidins
Protects hepatocytes against high glucose-induced apoptosis by modulating mitochondrial dysfunction.
102
Epigallocatechin gallate Increases the level of mitochondrial respiratory proteins, and in mtDNA content. 103 Curcumin Increases the respiratory chain complexes' activities.
104
Allyl-isothiocyanate Increases the respiratory chain complexes' activities and ameliorates insulin resistance. 105 Astaxanthin Maintains the mitochondrial membrane potential.
106
Silybin Increases the mitochondrial size, β-oxidation and ATP production. It can also improve the mitochondrial cristae organization and ameliorates the fatty acid-induced apoptotic signals.
107
T A B L E 1 Plant derived antioxidants acting at the mitochondria used in experimental non-alcoholic fatty liver disease However, a generalized antioxidant therapy alone was not able to deliver an expected beneficial effect. Keeping the role of mitochondria in NAFLD in mind, mitochondria-targeted antioxidant treatment may add a lot to a superior outcome. However, the selective permeability of IMM remains the major bottleneck to the targeted treatment.
Several agents have been tried so far to transport antioxidant to mitochondria ( Table 2) . A ubiquinol moiety covalently attached to a lipophilic triphenylphosphonium (TPP) cation called MitoQ is one among them. [84] [85] [86] The attached cation, TPP, can enter the negatively charged hydrophobic IMM. Therefore, the MitoQ may remain within the IMM and maintain its ubiquinone-ubiquinol form with the support of complex II of the ETC. In addition to this, the hydrophobic environment of IMM would never generate any free radical from the redox coupling status of ubiquinone.
Feeding rats with a high-fat diet and MitoQ for 8 weeks effectively increased the expression of cardiolipin synthase gene and its level in the liver mitochondria. 87 The MitoQ showed noticeable improvement in the manifestations of metabolic syndrome in rats fed a high-fat diet.
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Furthermore, previous studies demonstrated the antiapoptotic effect of MitoQ, which was mediated through the inhibition of cytochrome c release and caspase-3 activation. 89 It effectively blocked the ROSinduced transferrin receptor-mediated iron uptake in mitochondria, lipid peroxidation, lipid peroxide-induced inactivation of complex I, and aconitase. The combined effects of these mitigated the peroxide-mediated oxidative stress, maintained the proteasomal function, and inhibited apoptosis. 89 Mercer et al 90 recently demonstrated the efficacy of MitoQ against the metabolic syndrome by preventing the hypercholesterolemia, hypertriglyceridaemia, and adiposity. It inhibited the mtDNA oxidative damage, hyperglycaemia, and hepatic steatosis associated with the metabolic syndrome. The protective effect was also elucidated for TPP cation ligated vitamin E. 89 Post oral ingestion, MitoQ level was found to be distributed in liver, brain, and heart, achieving a steady state after 7−10 days without any toxic side effects. 10 weeks. The effect may probably be attributed to the antioxidant effect and, thus, prevented by the lipid peroxidation and protein carbonyl formation. 93, 94 Similarly, a mitochondria-targeted nitroxide, mitocarboxy proxyl was also demonstrated as an effective agent to inhibit the peroxide-mediated transferrin-iron uptake into mitochondria and ultimately, inhibiting apoptosis. 95 Despite several experimental studies, only a few high quality randomized vs placebo-controlled, doubleblinded trials have been carried out to assess the effect in humans.
| CONCLUSION AND FUTURE PERSPECTIVES
The fundamental pathophysiology of NAFLD can be described by multiple effects. The primary effect is initiated by the accumulation of hepatic fat. Among the various disease entities, non-alcoholic steatohepatitis is potentially the serious form, which may progress to scarring and irreversible damage. Non-alcoholic steatohepatitis, in the most severe cases, can progress to cirrhosis and liver failure.
Previous studies recommend the administration of pioglitazone and metformin. Pioglitazone can inhibit pyruvate-driven ATP synthesis and glucose production in isolated mitochondria from hepatocytes. 96 Further, it can prevent the cytochrome C leakage, stabilize the mitochondrial membrane potential, maintain the ATP production, inhibit the ROS generation and activities the ETC complexes I and III. 97 However, its role in NAFLD has not yet been evaluated.
Metformin has an effect on the energy transduction by selectively inducing a state in complex I. T A B L E 2 Mitochondria-targeted agents used in non-alcoholic fatty liver disease
